28125612|t|A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting
28125612|a|Cells of the innate and adaptive immune system are key factors in the progression of atherosclerotic plaque, leading to plaque instability and rupture, potentially resulting in acute atherothrombotic events such as coronary artery disease, cerebrovascular disease and peripheral arterial disease. Here, we describe the cloning, expression, purification, and immunoreactivity assessment of a recombinant single-chain variable fragment (scFv) derived from a human anti-αIIbβ3 antibody (HuAb) selected to target atheromatous lesions for the presence of platelets. Indeed, platelets within atheroma plaques have been shown to play a role in inflammation, in platelet - leucocyte aggregates and in thrombi formation and might thus be considered relevant biomarkers of atherosclerotic progression. The DNA sequence that encodes the anti-αIIbβ3 TEG4 scFv previously obtained from a phage-display selection on activated platelets, was inserted into the eukaryote vector (pPICZαA) in fusion with a tag sequence encoding 2 cysteines useable for specific probes grafting experiments. The recombinant protein was expressed at high yields in Pichia pastoris (30 mg/L culture). The advantage of P. pastoris as an expression system is the production and secretion of recombinant proteins in the supernatant, ruling out the difficulties encountered when scFv are produced in the cytoplasm of bacteria (low yield, low solubility and reduced affinity). The improved conditions allowed for the recovery of highly purified and biologically active scFv fragments ready to be grafted in a site -directed way to nanoparticles for the imaging of atherosclerotic plaques involving inflammatory processes and thus at high risk of instability.
28125612	2	13	Recombinant	T062	UMLS:C0017387
28125612	14	19	Human	T204	UMLS:C0086418
28125612	20	47	Anti-Platelet scFv Antibody	T103	UMLS:C0370058
28125612	34	38	scFv	T103	UMLS:C1883036
28125612	60	75	Pichia pastoris	T204	UMLS:C0997362
28125612	80	88	Atheroma	T038	UMLS:C0264956
28125612	99	104	Cells	T017	UMLS:C0007634
28125612	132	145	immune system	T022	UMLS:C0020962
28125612	169	180	progression	T038	UMLS:C0242656
28125612	184	206	atherosclerotic plaque	T031	UMLS:C2936350
28125612	219	225	plaque	T033	UMLS:C0332461
28125612	226	237	instability	T033	UMLS:C1444783
28125612	242	249	rupture	T037	UMLS:C3203359
28125612	282	298	atherothrombotic	T017	UMLS:C1963943
28125612	314	337	coronary artery disease	T038	UMLS:C0010054
28125612	339	362	cerebrovascular disease	T038	UMLS:C0007820
28125612	367	394	peripheral arterial disease	T038	UMLS:C0085096
28125612	418	425	cloning	T062	UMLS:C0525050
28125612	427	437	expression	T038	UMLS:C1171362
28125612	474	484	assessment	T058	UMLS:C0220825
28125612	502	532	single-chain variable fragment	T103	UMLS:C1883036
28125612	534	538	scFv	T103	UMLS:C1883036
28125612	555	560	human	T204	UMLS:C0086418
28125612	561	581	anti-αIIbβ3 antibody	T103	UMLS:C0016011
28125612	583	587	HuAb	T103	UMLS:C0016011
28125612	608	620	atheromatous	T038	UMLS:C0264956
28125612	621	628	lesions	T033	UMLS:C0221198
28125612	637	645	presence	T033	UMLS:C0150312
28125612	649	658	platelets	T017	UMLS:C0005821
28125612	668	677	platelets	T017	UMLS:C0005821
28125612	685	701	atheroma plaques	T031	UMLS:C2936350
28125612	736	748	inflammation	T038	UMLS:C0021368
28125612	753	761	platelet	T017	UMLS:C0005821
28125612	764	773	leucocyte	T017	UMLS:C0023516
28125612	792	799	thrombi	T038	UMLS:C0087086
28125612	848	858	biomarkers	T201	UMLS:C0005516
28125612	878	889	progression	T038	UMLS:C0242656
28125612	895	907	DNA sequence	T082	UMLS:C0162326
28125612	925	946	anti-αIIbβ3 TEG4 scFv	T103	UMLS:C1883036
28125612	974	997	phage-display selection	T062	UMLS:C3494191
28125612	1011	1020	platelets	T017	UMLS:C0005821
28125612	1026	1034	inserted	T038	UMLS:C1512796
28125612	1044	1053	eukaryote	T204	UMLS:C0684063
28125612	1054	1060	vector	T103	UMLS:C1514152
28125612	1062	1069	pPICZαA	T103	UMLS:C1514152
28125612	1088	1100	tag sequence	T082	UMLS:C0162326
28125612	1112	1121	cysteines	T103	UMLS:C0010654
28125612	1150	1170	grafting experiments	T058	UMLS:C0022885
28125612	1176	1195	recombinant protein	T103	UMLS:C0034861
28125612	1200	1209	expressed	T038	UMLS:C1171362
28125612	1228	1243	Pichia pastoris	T204	UMLS:C0997362
28125612	1253	1260	culture	T103	UMLS:C0010454
28125612	1280	1291	P. pastoris	T204	UMLS:C0997362
28125612	1298	1308	expression	T038	UMLS:C1171362
28125612	1338	1347	secretion	T038	UMLS:C0036536
28125612	1351	1371	recombinant proteins	T103	UMLS:C0034861
28125612	1379	1390	supernatant	T031	UMLS:C1550101
28125612	1437	1441	scFv	T103	UMLS:C1883036
28125612	1462	1471	cytoplasm	T017	UMLS:C0010834
28125612	1475	1483	bacteria	T007	UMLS:C0004611
28125612	1523	1531	affinity	T038	UMLS:C0003255
28125612	1538	1546	improved	T033	UMLS:C0184511
28125612	1606	1640	biologically active scFv fragments	T103	UMLS:C0574031
28125612	1626	1630	scFv	T103	UMLS:C1883036
28125612	1666	1670	site	T082	UMLS:C0205145
28125612	1710	1717	imaging	T058	UMLS:C0011923
28125612	1721	1744	atherosclerotic plaques	T031	UMLS:C2936350
28125612	1790	1802	high risk of	T033	UMLS:C0332167
28125612	1803	1814	instability	T033	UMLS:C1444783